| References |
1.
Isolation and characterization of dipeptidyl peptidase IV from human placenta.
G.Püschel et al., Eur. J. Biochem., 126, 359 (1982)
2.
Identification of genes involved in the suppression of antibody production from human peripheral blood lymphocytes.
Y.Aiba et al., Biosci. Biotechnol. Biochem., 70, 966 (2006)
3.
Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
D.L.Thiele and P.E.Lipsky, J. Immunol., 137, 1399 (1986)
4.
The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes.
M.Ohlin et al., Immunology, 66, 485 (1989)
5.
Generalized toxicity of L-leucyl-leucine-methyl ester for lymphocyte functions.
A.M.Mowat and P.A.Leck, Immunology, 69, 564 (1990)
6.
Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
M.H.Hsieh et al., Biol. Blood Marrow Transplant., 8, 303 (2002)
7.
Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.
J.Filicko-O’Hara et al., Biol. Blood Marrow Transplant., 15, 1609 (2009)
8.
Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells.
Thiele DL, et, al. Proc Natl Acad Sci U S A. 1990 Jan;87(1):83-7.
9.
The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
Thiele DL, et, al. J Immunol. 1986 Feb 1;136(3):1038-48. |
